Publications

Detailed Information

The effect of growth hormone on fibroblast proliferation and keratinocyte migration

DC Field Value Language
dc.contributor.authorLee, Sang Woo-
dc.contributor.authorKim, Suk Hwa-
dc.contributor.authorKim, Ji Youn-
dc.contributor.authorLee, Yoonho-
dc.date.accessioned2012-07-03T02:02:51Z-
dc.date.available2012-07-03T02:02:51Z-
dc.date.issued2010-04-
dc.identifier.citationJOURNAL OF PLASTIC, RECONSTRUCTIVE AND AESTHETIC SURGERY; Vol.63 4; E364-E369ko_KR
dc.identifier.issn1748-6815-
dc.identifier.urihttps://hdl.handle.net/10371/78186-
dc.description.abstractBackground: The beneficial effects of growth hormones (GHs) on wound healing have been reported. Although the mechanism of how GH promotes wound healing is unclear, there are reports showing that the principal factor lies in the GH-stimulated production of IGF-1 in topical wounds. In this study, a human primary cell model was devised to examine how the topical application of GHs affects fibroblast proliferation and keratinocyte migration, which play fundamental roles in wound healing. Methods: The fibroblasts were cultured in media with different concentrations of GH. The amount of fibroblast proliferation was assessed using a tetrazolium-based colourimetric assay (MTT assay). The amount of newly formed IGF-1 mRNA was measured by reverse transcription and polymerase chain reaction (RT-PCR). Keratinocyte migration was compared using a migration assay. Results: Fibroblast proliferation was significantly higher in the experimental group than in the control group (the absorbance of 2.5 IU L(-1) GH applied group: 0.3954 +/- 0.056, control group: 0.2943 +/- 0.0554, P < 0.05), and the promotion of IGF-1 formation by fibroblasts was observed. There was more keratinocyte migration in the experimental group than in the control group (the remaining gap in the 2.5 IU L(-1) GH applied group after keratinocyte migration: 46.57 +/- 2.22% of the primary gap, control group: 75.14 +/- 3.44%, P < 0.05). Conclusion: GH enhances the local formation of IGF-1, which activates fibroblast proliferation and keratinocyte migration. These results highlight the potential of the topical application of GHs in the treatment of wounds. (C) 2009 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by Elsevier Ltd. All rights reserved.ko_KR
dc.language.isoenko_KR
dc.publisherELSEVIER SCI LTDko_KR
dc.subjectGrowth hormoneko_KR
dc.subjectIGF-1ko_KR
dc.subjectKeratinocyteko_KR
dc.subjectFibroblastko_KR
dc.titleThe effect of growth hormone on fibroblast proliferation and keratinocyte migrationko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor이상우-
dc.contributor.AlternativeAuthor김석화-
dc.contributor.AlternativeAuthor김지윤-
dc.contributor.AlternativeAuthor이윤호-
dc.identifier.doi10.1016/j.bjps.2009.10.027-
dc.citation.journaltitleJOURNAL OF PLASTIC RECONSTRUCTIVE AND AESTHETIC SURGERY-
dc.description.citedreferenceLI JX, 2006, ZHONGHUA SHAO SHANG, V22, P33-
dc.description.citedreferenceJeschke MG, 2005, WOUND REPAIR REGEN, V13, P269-
dc.description.citedreferenceLi W, 2004, J INVEST DERMATOL, V123, P622, DOI 10.1111/j.0022-202X.2004.23416.x-
dc.description.citedreferenceThorey IS, 2004, J BIOL CHEM, V279, P26674, DOI 10.1074/jbc.M311467200-
dc.description.citedreferenceDunaiski V, 2002, GROWTH HORM IGF RES, V12, P381, DOI 10.1016/S1096-6374(02)00080-1-
dc.description.citedreferenceLosada F, 2002, WORLD J SURG, V26, P2-
dc.description.citedreferenceSinger AJ, 1999, NEW ENGL J MED, V341, P738-
dc.description.citedreferenceGuicheux J, 1998, BONE, V22, P25-
dc.description.citedreferencePIERRE EJ, 1997, J BURN CARE REHABIL, V18, P287-
dc.description.citedreferenceROBERTSON JG, 1997, WOUND REPAIR REGEN, V5, P168-
dc.description.citedreferenceJORGENSEN PH, 1996, WOUND REPAIR REGEN, V4, P40-
dc.description.citedreferenceSTEENFOS HH, 1994, SCAND J PLAST RECONS, V28, P95-
dc.description.citedreferenceRASMUSSEN LH, 1994, WOUND REPAIR REGEN, V2, P31-
dc.description.citedreferencePELL JM, 1992, ENDOCRINOLOGY, V130, P1942-
dc.description.citedreferenceSTEENFOS HH, 1992, J ENDOCRINOL, V132, P293-
dc.description.citedreferenceMERCHAV S, 1988, BRIT J HAEMATOL, V70, P267-
dc.description.citedreferenceGREEN H, 1985, DIFFERENTIATION, V29, P195-
dc.description.citedreferenceSCOTT CD, 1985, ENDOCRINOLOGY, V116, P1094-
dc.description.citedreferenceKURTZ A, 1985, J CLIN INVEST, V76, P1643-
dc.description.citedreferenceMOSMANN T, 1983, J IMMUNOL METHODS, V65, P55-
dc.description.citedreferenceBOYCE ST, 1983, J INVEST DERMATOL S, V81, P33-
dc.description.citedreferenceDIEGELMANN RF, 1979, J CELL PHYSIOL, V98, P341-
dc.description.tc4-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share